Vaxart Files 2024 Annual Report
Ticker: VXRT · Form: 10-K · Filed: Mar 20, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 10-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, biotech, financials
TL;DR
Vaxart's 2024 10-K is in. Check financials and future plans.
AI Summary
Vaxart, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its biopharmaceutical operations. The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is focused on developing oral vaccines. The filing details its financial performance and business activities for the period.
Why It Matters
This filing provides investors and the public with a comprehensive overview of Vaxart's financial health, strategic direction, and potential risks for the past fiscal year.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies like Vaxart often face high risks due to the nature of drug development, regulatory hurdles, and market competition.
Key Numbers
- 350,000,000 — Authorized Shares (Indicates the total number of shares the company is permitted to issue.)
- 250,000,000 — Outstanding Shares (Represents the number of shares currently held by investors.)
- 228,203,822 — Total Assets (Shows the company's total resources as of the fiscal year end.)
- 153,959,853 — Total Liabilities (Represents the company's total obligations.)
Key Players & Entities
- Vaxart, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
- South San Francisco, CA (location) — Business and mailing address
FAQ
What was Vaxart's primary business focus during the fiscal year 2024?
Vaxart, Inc. is a biopharmaceutical company focused on developing oral vaccines, as indicated by its SIC code for Biological Products.
What is Vaxart's principal executive office location?
Vaxart's business and mailing address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080.
How many shares of common stock was Vaxart authorized to issue as of December 31, 2024?
As of December 31, 2024, Vaxart, Inc. was authorized to issue 350,000,000 shares of common stock.
What were Vaxart's total assets and liabilities at the end of the 2024 fiscal year?
Total assets were $228,203,822 and total liabilities were $153,959,853 as of December 31, 2024.
Has Vaxart operated under any previous company names?
Yes, Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (name change April 13, 2016), Biota Pharmaceuticals, Inc. (name change November 13, 2012), and NABI BIOPHARMACEUTICALS (name change July 19, 2010).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding Vaxart, Inc. (VXRT).